UMCG Hopes for Fewer Baby Admissions After RSV Vaccine
Okay, I will create a extensive, SEO-optimized article based on the provided news snippets, adhering to all the specified guidelines. Here’s the HTML5 `
“`html
New RSV vaccine Offers Hope for protecting infants
Table of Contents
A newly developed shot promises protection against Respiratory Syncytial Virus (RSV), a common but potentially serious illness affecting hundreds of babies each year. This growth marks a significant step forward in pediatric healthcare.
What is RSV and Why is it Hazardous for Babies?
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for infants and young children, RSV can lead to bronchiolitis (inflammation of the small airways in the lungs) and pneumonia. According to the Centers for Disease Control and Prevention (CDC), RSV is the most common cause of bronchiolitis and pneumonia in children under one year of age in the United States.
Each year, an estimated 58,000 to 316,000 children under five years old are hospitalized with RSV infection. While most children recover, RSV can be severe and even fatal, particularly for premature babies, infants with underlying health conditions, and those with weakened immune systems. the CDC estimates that between 100 and 500 children die each year from RSV in the US.
The New RSV Vaccine: A Breakthrough in Prevention
A new vaccine, developed and tested by researchers at the University Medical Center Groningen (UMCG) in the Netherlands, offers a promising solution to protect infants from RSV.As reported by UMCG,the shot has shown significant efficacy in clinical trials.
The vaccine works by stimulating the mother’s immune system to produce antibodies that will be passed on to the baby,providing protection during the frist few months of life,when they are most vulnerable. This approach is known as maternal immunization. The vaccine is typically administered during pregnancy,ideally between 32 and 36 weeks gestation.
Who is Eligible for the RSV Vaccine?
Currently, the CDC recommends RSV vaccination for pregnant people during weeks 32 through 36 of pregnancy to protect their babies from RSV. This advice applies to all pregnant individuals, irrespective of prior RSV infection.
Additionally,the CDC recommends RSV immunization for adults 60 years and older,and for certain infants and young children at increased risk for severe RSV disease. These include infants younger than 8 months born during or entering their first RSV season, and children 8-19 months who are at high risk for severe RSV disease.
Timeline of RSV Vaccine Development and Approval
- 2010s: Early research and development of RSV vaccine candidates begin.
- 2022: Promising clinical trial results for maternal RSV vaccines are announced.
- August 2023: The FDA approves the first RSV vaccine for maternal use (Abrysvo, manufactured by Pfizer).
- September 2023: The FDA approves the first RSV vaccine for older adults (Arexvy, manufactured by GSK).
- November 2024: widespread implementation of the maternal RSV vaccine programme is underway.